CN116354849A - 一种亚胺化合物及其制备方法、用途 - Google Patents
一种亚胺化合物及其制备方法、用途 Download PDFInfo
- Publication number
- CN116354849A CN116354849A CN202111626483.2A CN202111626483A CN116354849A CN 116354849 A CN116354849 A CN 116354849A CN 202111626483 A CN202111626483 A CN 202111626483A CN 116354849 A CN116354849 A CN 116354849A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- chlorophenyl
- sodium
- potassium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 150000002466 imines Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims abstract description 17
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 18
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 8
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- DDVNLGGCSRULIL-UHFFFAOYSA-N (1-bromocyclopentyl)-(2-chlorophenyl)methanone Chemical compound ClC1=CC=CC=C1C(=O)C1(Br)CCCC1 DDVNLGGCSRULIL-UHFFFAOYSA-N 0.000 claims description 7
- 239000013558 reference substance Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 6
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 6
- QIJMMRNZBJHXRI-UHFFFAOYSA-N (2-chlorophenyl)-cyclopentylmethanone Chemical compound ClC1=CC=CC=C1C(=O)C1CCCC1 QIJMMRNZBJHXRI-UHFFFAOYSA-N 0.000 claims description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 239000012024 dehydrating agents Substances 0.000 claims description 4
- 239000002808 molecular sieve Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 claims description 2
- 229910015900 BF3 Inorganic materials 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- 229930182821 L-proline Natural products 0.000 claims description 2
- 239000002841 Lewis acid Substances 0.000 claims description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 2
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 229960000583 acetic acid Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003729 cation exchange resin Substances 0.000 claims description 2
- 229940023913 cation exchange resins Drugs 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 229940071870 hydroiodic acid Drugs 0.000 claims description 2
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 claims description 2
- -1 ketone bromide Chemical class 0.000 claims description 2
- 150000007517 lewis acids Chemical class 0.000 claims description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 2
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- MKNZKCSKEUHUPM-UHFFFAOYSA-N potassium;butan-1-ol Chemical compound [K+].CCCCO MKNZKCSKEUHUPM-UHFFFAOYSA-N 0.000 claims description 2
- AWDMDDKZURRKFG-UHFFFAOYSA-N potassium;propan-1-olate Chemical compound [K+].CCC[O-] AWDMDDKZURRKFG-UHFFFAOYSA-N 0.000 claims description 2
- WQKGAJDYBZOFSR-UHFFFAOYSA-N potassium;propan-2-olate Chemical compound [K+].CC(C)[O-] WQKGAJDYBZOFSR-UHFFFAOYSA-N 0.000 claims description 2
- 229960002429 proline Drugs 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 claims description 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 claims description 2
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 claims description 2
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 claims description 2
- WBQTXTBONIWRGK-UHFFFAOYSA-N sodium;propan-2-olate Chemical compound [Na+].CC(C)[O-] WBQTXTBONIWRGK-UHFFFAOYSA-N 0.000 claims description 2
- 229910000018 strontium carbonate Inorganic materials 0.000 claims description 2
- UUCCCPNEFXQJEL-UHFFFAOYSA-L strontium dihydroxide Chemical compound [OH-].[OH-].[Sr+2] UUCCCPNEFXQJEL-UHFFFAOYSA-L 0.000 claims description 2
- 229910001866 strontium hydroxide Inorganic materials 0.000 claims description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 claims description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims description 2
- MDDPTCUZZASZIQ-UHFFFAOYSA-N tris[(2-methylpropan-2-yl)oxy]alumane Chemical compound [Al+3].CC(C)(C)[O-].CC(C)(C)[O-].CC(C)(C)[O-] MDDPTCUZZASZIQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 5
- HIAIVILTZQDDNY-UHFFFAOYSA-J tin(4+);trifluoromethanesulfonate Chemical compound [Sn+4].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F HIAIVILTZQDDNY-UHFFFAOYSA-J 0.000 claims 1
- 239000000243 solution Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000012535 impurity Substances 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000005696 Diammonium phosphate Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 4
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 4
- 235000019838 diammonium phosphate Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- RBGLVWCAGPITBS-UHFFFAOYSA-L bis(trifluoromethylsulfonyloxy)tin Chemical compound [Sn+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F RBGLVWCAGPITBS-UHFFFAOYSA-L 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- ZJQKISPTWPQBSR-UHFFFAOYSA-N methanamine;toluene Chemical compound NC.CC1=CC=CC=C1 ZJQKISPTWPQBSR-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/50—Conditioning of the sorbent material or stationary liquid
- G01N30/52—Physical parameters
- G01N30/54—Temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明属于医药化学领域,具体涉及一种1‑(2‑氯苯基)‑1‑(环戊基‑1‑烯‑1‑基)‑N‑甲基亚胺(式A化合物)及其制备方法、用途。
Description
技术领域
本发明属于医药领域,具体提供了化合物1-(2-氯苯基)-1-(环戊基-1-烯-1-基)-N-甲基亚胺(式A化合物)及其制备方法、用途。
背景技术
抑郁症是一种以情绪低落为主要表现的常见精神疾病,造成患者社会功能丧失和生活质量下降,常导致患者并发其他躯体疾病甚至死亡。
2-(2-氯苯基)-2-(甲氨基)环己酮是一种临床上常用的麻醉药,在小儿麻醉中应用尤其广泛。2000年开始有研究发现,其具有非常迅速的抗抑郁作用,研究表明2-(2-氯苯基)-2-(甲氨基)环己酮与传统抗抑郁药相比,具有起效快、作用时间长、对难治性抑郁症疗效佳等特点,但少数抑郁症患者在使用2-(2-氯苯基)-2-(甲氨基)环己酮治疗后出现了精神活性副作用,包括出现解离症状、精神症状等。
为了保证用药安全,活性药物成分中的每一个杂质都必须进行安全性评估,即建立保证安全性的杂质限度。根据人用药品注册技术标准国际协调会(ICH)要求,原料药或其制剂组合物中的单个杂质量如果超过0.05%,应需要报告;单个杂质量如超过0.1%,就需要进行确证;单个杂质量如超过0.15%,则需要有安全性数据支持,因此,需要对杂质进行结构确认、含量控制,以满足药品制备的要求,为毒理学研究提供基础,同时也为合成工艺过程控制、原料药储存、制剂工艺控制、药品储存提供参考。
发明内容
本发明提供了化合物1-(2-氯苯基)-1-(环戊基-1-烯-1-基)-N-甲基亚胺(式A化合物)及其制备方法、用途。
本发明提供一种化合物1-(2-氯苯基)-1-(环戊基-1-烯-1-基)-N-甲基亚胺(式A化合物)制备方法,包括:
步骤1:将式1化合物(2-氯苯基)(环戊基)甲酮在加热条件下与溴代试剂得到式2化合物(1-溴代环戊基)(2-氯苯基)甲酮;
步骤2:将式2化合物(1-溴代环戊基)(2-氯苯基)甲酮在碱性试剂条件下加热进行消除反应得到式3化合物(2-氯苯基)(环戊基-1-烯-1-基)甲酮;
步骤3:将式3化合物(2-氯苯基)(环戊基-1-烯-1-基)甲酮溶于有机溶剂中,在脱水剂或催化剂作用下和甲胺缩合得到式A化合物1-(2-氯苯基)-1-(环戊基-1-烯-1-基)-N-甲基亚胺。
进一步地,所述的式A化合物的制备方法,步骤1中的加热条件为30-70℃,优选40-60℃,所述溴代试剂为溴素、溴化酮、N-溴代丁二酰亚胺(NBS)、溴化氢/过氧化氢、溴化钾/过氧化氢等,优选溴化氢/过氧化氢。
进一步地,所述的式A化合物的制备方法,步骤1中(2-氯苯基)(环戊基)甲酮:溴化氢:过氧化氢摩尔比=1:1.1~2.0:1.1~2.0,优选1:1.1~1.5:1.1~1.5。
进一步地,所述的式A化合物的制备方法,其特征在于,步骤2中的加热条件为80-140℃,优选90-120℃。
进一步地,所述的式A化合物的制备方法,其特征在于,所述步骤2中碱性试剂选自氢氧化钠、氢氧化钾、氢氧化锶、氢氧化锂、氢氧化钡、氢氧化钙、氢氧化铯、碳酸氢钠、碳酸氢钾、碳酸钠、碳酸钾、碳酸锶、碳酸铯、硫化钠、氢化钠、丁基锂、(六氢)吡啶、喹啉、甲醇钠、乙醇钠、丙醇钠、异丙醇钠、正丁醇钠、叔丁醇钠、甲醇钾、乙醇钾、丙醇钾、异丙醇钾、正丁醇钾、叔丁醇钾、二乙胺、三正丁胺、三丙基胺、二异丙基胺、二异丙基乙胺、叔丁醇铝、三乙胺或二甲氨基吡啶中的任意一种或多种;优选吡啶。
进一步地,所述的式A化合物的制备方法,其特征在于,步骤3中所述有机溶剂为甲苯、二氯甲烷、甲醇、乙醇,优选甲苯;所述脱水剂选自无水硫酸镁、无水硫酸钠、氯化钙、分子筛或氧化钙任意一种或多种,优选分子筛。
进一步地,所述的式A化合物的制备方法,其特征在于,步骤3中所述催化剂选自硫酸、盐酸、氢溴酸、氢碘酸、磷酸、硝酸、高氯酸、对甲苯磺酸、苯磺酸、阳离子交换树脂、乙酸、三氟乙酸、L-脯氨酸、三氟化硼、三甲基铝、四氯化钛、三氟甲磺酸锡、氯化铝、氯化镍等质子酸、路易斯酸的一种或多种,优选四氯化钛。
本发明还提供一种式A化合物在2-(2-氯苯基)-2-(甲氨基)环己酮、(R)异构体、(S)异构体或可药用盐原料药、制剂的有关物质检测时作为对照品的用途,
本发明还提供一种2-(2-氯苯基)-2-(甲氨基)环己酮、(R)异构体、(S)异构体或其可药用盐的原料药,其中式A化合物含量低于0.2%,优选低于0.1%,更优选低于0.015%。
本发明提供一种化合物1-(2-氯苯基)-1-(环戊基-1-烯-1-基)-N-甲基亚胺(式A化合物),
本发明的一个实施例方案中,所述盐酸2-(2-氯苯基)-2-(甲氨基)环己酮包括但不限于注射剂、鼻喷剂、胶囊剂、片剂、贴剂、锭剂、混悬剂、糖浆剂或膏剂等形式,优选注射剂。
具体实施方式
以下将结合实施例更详细地解释本发明,本发明的实施例仅用于说明本发明的技术方案,本发明的实质和范围并不局限于此。
实施例1
步骤1:制备式2化合物((1-溴代环戊基)(2-氯苯基)甲酮)
将24.00g(2-氯苯基)(环戊基)甲酮和25.00g氢溴酸(48%)水溶液加入反应瓶中,开启搅拌(快速),控制内温于40-60℃滴加14.00g双氧水,滴毕,控温于50-60℃下保温搅拌1小时。
计时毕,将反应液冷却,于20-30℃加入150mL正庚烷和150mL15%亚硫酸钠水溶液,搅拌30分钟,分液,有机相再用15%亚硫酸钠水溶液洗两次(80mL/次),有机相用无水硫酸镁干燥,过滤,滤饼用25mL正庚烷淋洗,滤液于50-60℃下减压浓缩蒸除溶剂,得30.32g(1-溴代环戊基)(2-氯苯基)甲酮(黄色油状物),收率96.4%。
步骤2:制备式3化合物((2-氯苯基)(环戊基-1-烯-1-基)甲酮)
将26.40g(1-溴代环戊基)(2-氯苯基)甲酮和135ml吡啶加至反应瓶,加热至105℃并于105-115℃保温反应,TLC监测反应。
反应毕,减压蒸除溶剂;向其中加入180ml乙酸乙酯,用10%的柠檬酸水溶液洗三次(80ml/次),用无水硫酸镁干燥,抽滤,滤液减压蒸除溶剂,得深棕色油状物,加入150ml二氯甲烷、150ml石油醚和15.00g硅胶搅拌10分钟,过滤,滤液减压蒸除溶剂,得到12.18g浅黄色油状物。
步骤3:制备式A化合物(1-(2-氯苯基)-1-(环戊基-1-烯-1-基)-N-甲基亚胺)
将8.90g(2-氯苯基)(环戊基-1-烯-1-基)甲酮和90ml甲胺甲苯混合溶液加至反应瓶,搅拌下用冰水浴降温,至5℃滴加16.33g四氯化钛,控温在0-20℃滴加,滴加完毕,于15-25℃下反应。
反应毕,反应液用冰水浴降温,加入100ml乙酸乙酯和100ml水,用氨水调pH为9-10,过滤(滤纸上铺一层硅藻土),滤饼用100ml乙酸乙酯洗涤,滤液分液,有机相用水洗两次(100ml/次),用无水硫酸镁干燥,过滤,滤液减压蒸除溶剂,得到7.90g式A化合物。
氢谱归属如下:
1H NMR(400MHz,CDCl3)δ1.98–2.00(dd,J=7.30,3.67Hz,2H),2.45(s,2H),2.76(s,2H),3.08(s,3H),5.56(s,1H),7.07–7.08(d,1H),7.32–7.44(m,3H)。
(+)-ESI-TOF/MS高分辨质谱测得相应的[M+H]+离子峰(m/z 220.0885),测得其离子式准确质量与C13H15ClN+的元素组成一致。二级质谱采集模式Target MS/MS,碰撞能量CID 20eV,测得其[M+H]+的主要碎片离子峰m/z分别为:163.0307、156.0927、128.0615、125.0150与1-(2-氯苯基)-1-(环戊基-1-烯-1-基)-N-甲基亚胺结构特征相对应。
实施例2
精密称取2-(2-氯苯基)-2-(甲氨基)环己酮盐酸盐供试品10mg,置10mL量瓶中,用流动相A溶解并稀释至刻度,摇匀,作为供试品溶液;精密称取式A化合物、式3化合物对照品适量,置同一量瓶中,用乙腈溶解并稀释制成每1ml中含式A化合物、式3化合物均为10μg的混合溶液,作为杂质对照品贮备液;另精密称取2-(2-氯苯基)-2-(甲氨基)环己酮盐酸盐对照品约10mg,置10mL量瓶中,加杂质对照品贮备液1ml,用流动相A溶解并稀释至刻度,摇匀,作为系统适用性溶液。
照高效液相色谱法(中国药典2020年版四部通则0512)测定,用十八烷基硅烷键合硅胶为填充剂;以0.01mol/L磷酸氢二铵溶液(取磷酸氢二铵1.32g,加水1000ml使溶解,加三乙胺0.5ml,用磷酸调节pH值至7.5)-乙腈(80:20)为流动相A,0.01mol/L磷酸氢二铵溶液(取磷酸氢二铵1.32g,加水1000ml使溶解,加三乙胺0.5ml,用磷酸调节pH值至7.5)-乙腈(20:80)为流动相B,按下表进行线性梯度洗脱;流速为每分钟1.0ml;柱温为30℃;检测波长为215nm;进样体积20μl。
精密量取系统适用性溶液20μl注入液相色谱仪,记录色谱图。(2-(2-氯苯基)-2-(甲氨基)环己酮盐酸盐与式A化合物依次出峰,各峰之间的分离度均应符合要求。系统适用性符合要求后对供试品溶液进行检测。
系统适用性溶液检测结果见下表1:
表1系统适用性溶液检测结果
通过上述实施例2的结果可知,本发明提供的式A化合物作为(2-(2-氯苯基)-2-(甲氨基)环己酮盐酸盐及其(R)异构体、(S)异构体或其药物组合物的杂质对照品,可用于其质量控制,对(2-(2-氯苯基)-2-(甲氨基)环己酮及其(R)异构体、(S)异构体或其药物组合物的质量监控具有非常重要的作用。
尽管以上已经对本发明作了详细描述,但是本领域技术人员理解,在不偏离本发明的精神和范围的前提下,可以对本发明进行各种修改和改变。本发明的权利范围并不限于上文所作出的详细描述,而应当属于权利要求书。
Claims (10)
2.如权利要求1所述的式A化合物的制备方法,其特征在于,步骤1中的加热条件为30-70℃,优选40-60℃,所述溴代试剂为溴素、溴化酮、N-溴代丁二酰亚胺(NBS)、溴化氢/过氧化氢、溴化钾/过氧化氢等,优选溴化氢/过氧化氢。
3.如权利要求2所述的式A化合物的制备方法,其特征在于,步骤1中的式1化合物(2-氯苯基)(环戊基)甲酮:溴化氢:过氧化氢摩尔比=1:1.1~2.0:1.1~2.0,优选1:1.1~1.5:1.1~1.5。
4.如权利要求1所述的式A化合物的制备方法,其特征在于,步骤2中的加热条件为80-140℃,优选90-120℃。
5.如权利要求1所述的式A化合物的制备方法,其特征在于,步骤2中碱性试剂选自氢氧化钠、氢氧化钾、氢氧化锶、氢氧化锂、氢氧化钡、氢氧化钙、氢氧化铯、碳酸氢钠、碳酸氢钾、碳酸钠、碳酸钾、碳酸锶、碳酸铯、硫化钠、氢化钠、丁基锂、(六氢)吡啶、喹啉、甲醇钠、乙醇钠、丙醇钠、异丙醇钠、正丁醇钠、叔丁醇钠、甲醇钾、乙醇钾、丙醇钾、异丙醇钾、正丁醇钾、叔丁醇钾、二乙胺、三正丁胺、三丙基胺、二异丙基胺、二异丙基乙胺、叔丁醇铝、三乙胺或二甲氨基吡啶中的任意一种或多种;优选吡啶。
6.如权利要求1所述的式A化合物的制备方法,其特征在于,步骤3中所述有机溶剂为甲苯、二氯甲烷、甲醇、乙醇,优选甲苯;所述脱水剂选自无水硫酸镁、无水硫酸钠、氯化钙、分子筛或氧化钙任意一种或多种,优选分子筛。
7.如权利要求1所述的式A化合物的制备方法,其特征在于,步骤3中所述催化剂选自硫酸、盐酸、氢溴酸、氢碘酸、磷酸、硝酸、高氯酸、对甲苯磺酸、苯磺酸、阳离子交换树脂、乙酸、三氟乙酸、L-脯氨酸、三氟化硼、三甲基铝、四氯化钛、三氟甲磺酸锡、氯化铝、氯化镍等质子酸、路易斯酸的一种或多种,优选四氯化钛。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111626483.2A CN116354849A (zh) | 2021-12-28 | 2021-12-28 | 一种亚胺化合物及其制备方法、用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111626483.2A CN116354849A (zh) | 2021-12-28 | 2021-12-28 | 一种亚胺化合物及其制备方法、用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116354849A true CN116354849A (zh) | 2023-06-30 |
Family
ID=86925418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111626483.2A Pending CN116354849A (zh) | 2021-12-28 | 2021-12-28 | 一种亚胺化合物及其制备方法、用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116354849A (zh) |
-
2021
- 2021-12-28 CN CN202111626483.2A patent/CN116354849A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6800842B2 (ja) | プリドピジンの類似体、それらの製造および使用 | |
EP1726304A1 (en) | Solifenacin-containing composition | |
EP1714965A1 (en) | Composition containing solifenacin succinate | |
CN111410658B (zh) | 咪达唑仑或其药物组合物的杂质a和杂质b及其用途 | |
CN102702008B (zh) | 阿戈美拉汀硫酸复合物及其制备方法 | |
CN103864774B (zh) | 一种鲁拉西酮的制备方法 | |
CN106995397A (zh) | R‑氨磺必利药用盐、制备方法、晶型及其用途 | |
EP2690087B1 (en) | New crystal form vii of agomelatine, preparation method and use thereof and pharmaceutical composition containing same | |
JP5986635B2 (ja) | 5,6,7,8−テトラヒドロ−6−[n,n−ビス[(2−チエニル)エチル]]アミノ−1−ナフトール、及びその作製方法、及びその使用 | |
CN116354849A (zh) | 一种亚胺化合物及其制备方法、用途 | |
CN113956197A (zh) | 一种马来酸氯苯那敏杂质的制备方法 | |
CN112028887B (zh) | 一种盐酸戊乙奎醚杂质及其制备方法 | |
CN105431409A (zh) | 制备阿福特罗或其盐的方法 | |
CN102718675A (zh) | 阿戈美拉汀甲磺酸复合物及其制备方法 | |
CN112724046A (zh) | 一种帕拉米韦杂质f及其制备方法和用途 | |
CN112266341A (zh) | 一种帕拉米韦中间体9杂质f及其制备方法和用途 | |
CN108929269B (zh) | 苄异喹啉类非去极化肌松剂及其制备方法和用途 | |
CN114364658A (zh) | 一种左旋吡喹酮及其手性中间体的制备方法和组合物 | |
CN107778290B (zh) | 一种喹啉衍生物的杂质及其制备方法 | |
CN112409338B (zh) | 一种盐酸咪达唑仑糖浆杂质c和杂质d及其用途 | |
CN112441982B (zh) | 一种盐酸咪达唑仑糖浆杂质a和杂质b及其用途 | |
WO2024060271A1 (zh) | 一种恩格列净原料药或制剂中的特征杂质及其应用 | |
CN103910704B (zh) | 一种奈必洛尔的制备方法及其中间体化合物 | |
US20070191425A1 (en) | Solifenacin-containing composition | |
CN102218063A (zh) | 盐酸丙哌维林药物的制备方法和产品及其检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |